March-In Rights and Should the Government Be Using Them to Control Drug Prices?

A march-in right, currently as it stands under federal law, allows an agency that funds private research to require a drug maker to license its patent to another party in order to “alleviate health and safety needs which are not being reasonably satisfied” or when the benefit of a drug are not available on “reasonable terms.” However, Dr. Francis Collins the director of the National Institutes of Health questioned whether or not the federal law permits the use of march-in rights to address drug pricing and what would be the consequences to the pharmaceutical industry. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.